SS Innovations International Inc. Common Stock
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems. The company also develops NADI " Automated Coronary Anastomotic Connector, a micro stapling device; SSi Multi-Fire Clip Applier, a cartridge-based clip applicator; SSi Robotic Stapler; SSi Maya " XR Pre-Operative Simulator, a robotic surgery platform; SSi Holographic Anatomy, an augmented reality tool; SSi Chitrasa " Advanced DICOM Viewer, an AI enabled application viewer; and SSi Mixed Reality Headset, a medical-grade device. In addition, it offers instrument tips, including forceps, scissors, electrocautery tools, scalpels, and other surgical tools. Further, the company provides accessory products, such as sterile drapes, 3d stereo endoscopes, cannulas, and seals, as well as tele proctoring and telesurgery products. Additionally, it offers installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring services. The company sells its products through direct sales organizations and distributor networks. SS Innovations International, Inc. is headquartered in Gurugram, India.
Open SSII dashboard ↗Beyond Air, Inc. Common Stock
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Open XAIR dashboard ↗